InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,245.60
(
-0.07%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.99
(
-0.02%
)
Bitcoin
64,050.21
(
-1.19%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: ariadndndough post# 32233

Monday, 07/15/2013 7:31:10 PM

Monday, July 15, 2013 7:31:10 PM

Post# of 80490
Changes to '113 trial...added 5th Cohort for brain mets...

Trial size increased from 130 to 175.

Narrowed cohort #3 to EGFR with T790M.

Added new cohort #5: NSCLC patients whose tumors exhibit ALK rearrangements and who have active, measurable brain metastases:
-Either crizotinib naive or resistant;
-Have at least one measurable brain lesion
-Previously untreated brain metastases with radiologically documented new or progressing brain lesions.


Sounds like 1st line ALK with brain mets to me.


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up